Last reviewed · How we verify
NCT05833217
Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
NA trial testing Adipose Tissue Biopsy in Long COVID in 55 participants. Currently enrolling.
2 May 2025
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 55 |
| Start date | 6 June 2023 |
| Primary completion | 2 May 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Adipose Tissue Biopsy
- Steady State Plasma Glucose (SSPG) Test
Conditions studied
- Long COVID — all drugs for Long COVID →
- Insulin Resistance — all drugs for Insulin Resistance →
- Insulin Sensitivity — all drugs for Insulin Sensitivity →
Sponsor
Stanford University
Who can join
Adults 18 to 80, any sex, with Long COVID or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05833217
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Long COVID
Currently open trials in the same condition.
- NCT05931497 — Sauna for Long Covid · NA · recruiting
- NCT06452095 — Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy fo · NA · recruiting
- NCT07316127 — Immunoadsorption in Autoimmune Long COVID · Phase 2 · recruiting
- NCT07435805 — Long-Term Health Effects of Previous COVID-19 in Patients Undergoing Preoperative Anesthesia Evaluation · recruiting
- NCT07278206 — Brain Stimulation in Long COVID · NA · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05833217 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 4 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05833217.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing